Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global Payments Inc (GPN) vs Viatris Inc (VTRS) Price & Performance

Global Payments IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Global Payments Inc vs Viatris Inc — how do they compare? Global Payments Inc trades at $82.2 (market cap $21.46B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Global Payments Inc and Viatris Inc are close in size by market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and Viatris Inc for 57 Days on average.

GPNVTRS
Market Cap
$21.46B$20.03B
Volume
1,482,60014,109,977
Sector
FinancialsHealth
52-Week High
$94.83$18.27
52-Week Low
$62.47$9.74
Typical Hold Time
50 Days57 Days
Enterprise Value
$39.60B$32.15B
Dividend Yield
1.23%2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global Payments Inc

Global Payments (GPN) trades at $82.77, up 2.08% with neutral technical signals and bullish moving averages. The company shows strong earnings momentum with three consecutive quarterly beats, though 2026 projections indicate potential profitability challenges. Recent developments include the Genius platform expansion and Worldpay integration driving growth opportunities, while elevated debt levels and competitive pressures present headwinds.

The stock offers 24% upside to the $102.75 consensus target with strong analyst support (59% buy ratings), but investors face risks from declining 2026 profitability projections and rising debt-to-asset ratios. The company's digital payment initiatives provide growth catalysts, though execution risks and margin pressures require careful monitoring.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GPN

No sentiment data available yet.

VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Global Payments Inc

Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.

Read more on GPN →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →